申请人:Munoz A. Julio
公开号:US20060122237A1
公开(公告)日:2006-06-08
Patients susceptible to or suffering from conditions and disorders, such as central nervous system disorders, are treated by administering to a patient in need thereof compositions that are hydroxybenzoate salts of E-metanicotine-type compounds. The formation of hydroxybenzoate salts of the E-metanicotine compounds is also useful in purifying the E-metanicotine compounds, as the hydroxybenzoate salts tend to crystallize out, leaving impurities such as Z-metanicotine compounds, and compounds where the double bond has migrated, in solution. If desired, the hydroxybenzoate salts can be converted to either the free base (the E-metanicotine) or to another pharmaceutically acceptable salt form.
易感或患有中枢神经系统疾病等状况的患者,通过向需要治疗的患者施用氢氧基苯酸盐型的E-甲基烟碱类化合物来进行治疗。形成E-甲基烟碱化合物的氢氧基苯酸盐也可用于纯化E-甲基烟碱化合物,因为氢氧基苯酸盐倾向于结晶出来,留下杂质,如Z-甲基烟碱化合物和双键迁移的化合物在溶液中。如果需要,氢氧基苯酸盐可以转化为自由基(E-甲基烟碱)或其他药学上可接受的盐形式。